SEARCH

SEARCH BY CITATION

References

  • Aandahl EM, Aukrust P, Skalhegg BS, Muller F, Froland SS, Hansson V et al. (1998). Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J 12: 855862.
  • Aandahl EM, Aukrust P, Muller F, Hansson V, Tasken K, Froland SS (1999). Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART. AIDS 13: F109F114.
  • Aandahl EM, Moretto WJ, Haslett PA, Vang T, Bryn T, Tasken K et al. (2002). Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J Immunol 169: 802808.
  • Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF (2004). Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78: 24542459.
  • Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A et al. (2004). TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol 173: 48474858.
  • Algrain M, Turunen O, Vaheri A, Louvard D, Arpin M (1993). Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. J Cell Biol 120: 129139.
  • Aricha R, Feferman T, Souroujon MC, Fuchs S (2006). Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB J 20: 374376.
  • Aukrust P, Aandahl EM, Skalhegg BS, Nordoy I, Hansson V, Tasken K et al. (1999). Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J Immunol 162: 11781185.
  • Baillie GS, Scott JD, Houslay MD (2005). Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 579: 32643270.
  • Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G et al. (2005). Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175: 14831490.
  • Bjorgo E, Solheim SA, Abrahamsen H, Baillie GS, Brown KM, Berge T et al. (2010). Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase a signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex. Mol Cell Biol 30: 16601672.
  • Bluestone JA, Abbas AK (2003). Natural versus adaptive regulatory T cells. Nat Rev Immunol 3: 253257.
  • Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E et al. (2007). Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 204: 13031310.
  • Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, Angelisova P et al. (2000). Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med 191: 15911604.
  • Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S et al. (2006). Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 13651371.
  • Bretscher A, Edwards K, Fehon RG (2002). ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3: 586599.
  • Brosens LA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH et al. (2005). Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. Clin Cancer Res 11: 40904096.
  • Bryn T, Mahic M, Enserink JM, Schwede F, Aandahl EM, Tasken K (2006). The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J Immunol 176: 73617370.
  • Cadogan M, Dalgleish AG (2008). Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines. Clin Med 8: 267271.
  • Carlson CR, Lygren B, Berge T, Hoshi N, Wong W, Tasken K et al. (2006). Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J Biol Chem 281: 2153521545.
  • Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. (2007). Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204: 12571265.
  • Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP et al. (2002). Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med 80: 1624.
  • Douek DC, Picker LJ, Koup RA (2003). T cell dynamics in HIV-1 infection. Annu Rev Immunol 21: 265304.
  • Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 11831188.
  • Essayan DM (2001). Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108: 671680.
  • Fujino H, Toyomura K, Chen X, Regan JW, Murayama T (2011). Prostaglandin E2 regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells. Biochem Pharmacol 81: 379387.
  • Fuld S, Borland G, Yarwood SJ (2005). Elevation of cyclic AMP in Jurkat T-cells provokes distinct transcriptional responses through the protein kinase A (PKA) and exchange protein activated by cyclic AMP (EPAC) pathways. Exp Cell Res 309: 161173.
  • Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA et al. (2007). Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445: 771775.
  • Gerlo S, Verdood P, Hooghe-Peters EL, Kooijman R (2006). Multiple cAMP-induced signaling cascades regulate prolactin expression in T cells. Cell Mol Life Sci 63: 9299.
  • Giembycz MA (2008). Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 155: 288290.
  • Giorgi JV, Lyles RH, Matud JL, Yamashita TE, Mellors JW, Hultin LE et al. (2002). Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 29: 346355.
  • Gloerich M, Bos JL (2010). Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 50: 355375.
  • Gupta RA, DuBois RN (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 1121.
  • Hanoune J, Defer N (2001). Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41: 145174.
  • Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM et al. (2003). Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17: 18811888.
  • Holm AM, Aukrust P, Aandahl EM, Muller F, Tasken K, Froland SS (2003). Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency–involvement of protein kinase A type I. J Immunol 170: 57725777.
  • Holm M, Pettersen FO, Kvale D (2008). PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples. Curr HIV Res 6: 4958.
  • Huang B, Zhao J, Lei Z, Shen S, Li D, Shen GX et al. (2009). miR-142-3p restricts cAMP production in CD4+. EMBO Rep 10: 180185.
  • Jarnaess E, Ruppelt A, Stokka AJ, Lygren B, Scott JD, Tasken K (2008). Dual specificity A-kinase anchoring proteins (AKAPs) contain an additional binding region that enhances targeting of protein kinase A type I. J Biol Chem 283: 3370833718.
  • Johansson CC, Bryn T, Aandahl EM, Areklett MA, Aukrust P, Tasken K et al. (2004). Treatment with type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected patients on highly active antiretroviral therapy. AIDS 18: 951952.
  • Kammer GM (1988). The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 9: 222229.
  • Kaupp UB, Seifert R (2002). Cyclic nucleotide-gated ion channels. Physiol Rev 82: 769824.
  • Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K et al. (2000). Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 404: 9991003.
  • Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR (2006). T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J Immunol 177: 67806786.
  • Kraus S, Arber N (2011). Cancer: do aspirin and other NSAIDs protect against colorectal cancer? Nat Rev Gastroenterol Hepatol 8: 125126.
  • Kvale D, Aaberge IS, Froland SS (2002). Predictive value of immunologic parameters and HIV RNA in relation to humoral pneumococcal polysaccharide vaccine responses in patients with HIV infection. Eur J Clin Microbiol Infect Dis 21: 688690.
  • Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM et al. (2006). Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS 20: 813820.
  • Levy FO, Rasmussen AM, Tasken K, Skalhegg BS, Huitfeldt HS, Funderud S et al. (1996). Cyclic AMP-dependent protein kinase (cAK) in human B cells: co-localization of type I cAK (RI alpha 2 C2) with the antigen receptor during anti-immunoglobulin-induced B cell activation. Eur J Immunol 26: 12901296.
  • Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X et al. (2007). Tumor evasion of the immune system by converting CD4+. J Immunol 178: 28832892.
  • Loza MJ, Penn RB (2010). Regulation of T cells in airway disease by beta-agonist. Front Biosci (Schol Ed) 2: 969979.
  • Mahic M, Yaqub S, Johansson CC, Tasken K, Aandahl EM (2006). FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 177: 246254.
  • Mandapathil M, Whiteside TL (2011). Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E cooperation. Expert Opin Biol Ther 11: 12031214.
  • Mosenden R, Tasken K (2011). Cyclic AMP-mediated immune regulation–overview of mechanisms of action in T cells. Cell Signal 23: 10091016.
  • Mosenden R, Singh P, Cornez I, Heglind M, Ruppelt A, Moutschen M et al. (2011). Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced immunodeficiency. J Immunol 186: 51195130.
  • Nayjib B, Zeddou M, Drion P, Boniver J, Tasken K, Rahmouni S et al. (2008). In vivo administration of a PKA type I inhibitor (Rp-8-Br-cAMPS) restores T-cell responses in retrovirus-infected mice. Open Immunol J 1: 2024.
  • Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD et al. (2001). Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 98: 27362744.
  • Oberprieler NG, Lemeer S, Kalland ME, Torgersen KM, Heck AJ, Tasken K (2010). High-resolution mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells. Blood 116: 22532265.
  • Pettersen FO, Tasken K, Kvale D (2010). Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection. Clin Exp Immunol 161: 315323.
  • Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M et al. (2011). An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol 85: 65576566.
  • Psaty BM, Potter JD (2006). Risks and Benefits of Celecoxib to Prevent Recurrent Adenomas. NEJM 355: 950952.
  • Rahmouni S, Anadahl EM, Trebak M, Boniver J, Tasken K, Moutschen M (2001). Increased cAMP levels and protein kinase (PKA) type I activation in CD4+ T cells and B cells contribute to the retrovirus-induced immunodeficiency of mice (MAIDS). A useful in vivo model for drug testing in PKA type I-induced immunodeficiency. FASEB J 15: 14661468.
  • Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M et al. (2006). Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296: 14981506.
  • Ruppelt A, Mosenden R, Gronholm M, Aandahl EM, Tobin D, Carlson CR et al. (2007). Inhibition of T cell activation by cyclic adenosine 5′-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. J Immunol 179: 51595168.
  • Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M et al. (2001). Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 1832.
  • Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z et al. (2006). Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 827.
  • Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F et al. (2005). Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 65: 52115220.
  • Sheng H, Shao J, Washington MK, DuBois RN (2001). Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 1807518081.
  • Skalhegg BS, Landmark BF, Doskeland SO, Hansson V, Lea T, Jahnsen T (1992). Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3′,5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem 267: 1570715714.
  • Skalhegg BS, Tasken K, Hansson V, Huitfeldt HS, Jahnsen T, Lea T (1994). Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex. Science 263: 8487.
  • Souness JE, Aldous D, Sargent C (2000). Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47: 127162.
  • de Souza AP, Bonorino C (2009). Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 9: 13171332.
  • Steffensen KD, Waldstrom M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A (2007). The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer 17: 798807.
  • Stokka AJ, Mosenden R, Ruppelt A, Lygren B, Tasken K (2010). The adaptor protein EBP50 is important for localization of the protein kinase A-Ezrin complex in T-cells and the immunomodulating effect of cAMP. Biochem J 425: 381388.
  • Takeuchi S, Takayama Y, Ogawa A, Tamura K, Okada M (2000). Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk. J Biol Chem 275: 2918329186.
  • Tanaka H, Tanaka J, Kjaergaard J, Shu S (2002). Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25: 207217.
  • Torgersen KM, Vaage JT, Levy FO, Hansson V, Rolstad B, Tasken K (1997). Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity. J Biol Chem 272: 54955500.
  • Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Horejsi V, Schraven B et al. (2001). Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts. J Biol Chem 276: 2931329318.
  • Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K (2002). Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal 14: 19.
  • Torgersen KM, Aandahl EM, Tasken K (2008). Molecular architecture of signal complexes regulating immune cell function. Handb Exp Pharmacol 186: 327363.
  • Torheim EA, Ndhlovu LC, Pettersen FO, Larsen TL, Jha AR, Torgersen KM et al. (2009). Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. Eur J Immunol 39: 12801287.
  • Treves AJ, Ligumski M, Fuks Z, Haimovitz A, Rachmilewitz D (1982). Prostaglandin E2 secretion by subsets of human peripheral blood monocytes. Immunopharmacology 4: 267276.
  • Tsujii M, Kawano S, DuBois RN (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 33363340.
  • Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S (1994). ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 126: 391401.
  • Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skalhegg BS et al. (2001). Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med 193: 497507.
  • Vang T, Abrahamsen H, Myklebust S, Horejsi V, Tasken K (2003). Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase a inhibits T cell receptor signaling. J Biol Chem 278: 1759717600.
  • Willoughby D, Cooper DM (2007). Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 87: 9651010.
  • Yaqub S, Tasken K (2008). Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. Crit Rev Oncog 14: 5777.
  • Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjornbeth BA et al. (2008). Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 57: 813821.
  • Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, Tsukita S et al. (1998). Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 140: 885895.